Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)

Michael Untch, Jens Huober, Christian Jackisch, Andreas Schneeweiss, Sara Y Brucker, Peter Dall, Carsten Denkert, Peter A Fasching, Tanja Fehm, Bernd Gerber, Wolfgang Janni, Thorsten Kühn, Diana Lüftner, Volker Möbus, Volkmar Müller, Achim Rody, Peter Sinn, Marc Thill, Christoph Thomssen, Nadia HarbeckCornelia Liedtke

Abstract

The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists. Five of the breast cancer specialists from Germany were also members of this year's St. Gallen panel. A comparison between the St. Gallen recommendations and the annually updated treatment guidelines of the Gynecologic Oncology Group (AGO 2017) and the S3-guideline agreed upon in 2017 is useful. The recommendations of the St. Gallen panel represent an international cross-section of opinions of experts from different countries and different disciplines, while the S3-guideline and AGO guidelines are evidence-based. The motto of this year's 15th St. Gallen Conference was "Escalating and De-Escalating". The rationale behind this concept was to promote more individualized treatment and thereby reduce overtreatment as well as undertreatment.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Volume77
Issue number6
Pages (from-to)633-644
Number of pages12
ISSN0016-5751
DOIs
Publication statusPublished - 06.2017

Fingerprint

Dive into the research topics of 'Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)'. Together they form a unique fingerprint.

Cite this